Keytruda is now approved for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) mutations/megabase] solid tumors.- Merck inc.
Merck Inc., announced that the FDA has approved Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [ greater than 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.